Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534892 · ClinicalTrials.gov registry record · Phase 3
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
A Phase 3 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 3
- Development phase
- 10,212
- Enrollment target
- 20
- Study locations
NCT06534892: Active Phase 3 study of Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline.
NCT06534892 is a Phase 3 study of Respiratory Syncytial Virus Infections that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 10,212 participants, above the 605-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (1588% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06534892, a Phase 3 study of Respiratory Syncytial Virus Infections, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 10,212 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Conditions Studied
Interventions
- BIOLOGICAL RSVPreF3 OA vaccine
Study Locations (20)
Florida
- GSK Investigational Site - Doral
- GSK Investigational Site - Fort Myers
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Lake City
- GSK Investigational Site - Melbourne
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
- GSK Investigational Site - Pinellas Park
- GSK Investigational Site - The Villages
- GSK Investigational Site - West Palm Beach
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Huntsville
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Savannah
California
- GSK Investigational Site - Cerritos
Illinois
- GSK Investigational Site - Chicago
Indiana
- GSK Investigational Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,212 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
What the registry record for NCT06534892 still lists
NCT06534892 is an interventional study that assigns participants to a tested intervention. Its 10,212 participants enrollment target places it among the larger protocols in the corpus, above the 605-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (1588% higher).
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 1 intervention - of which RSVPreF3 OA vaccine is the first listed.
NCT06534892 names 20 study sites across 7 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06534892 about?
NCT06534892 is a clinical study titled "An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study". The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the ...
What is the current status of trial NCT06534892?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 10,212 participants. The study started on 2024-08-01. Estimated completion is 2026-09-30.
What conditions does trial NCT06534892 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT06534892?
The interventions under investigation include: RSVPreF3 OA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06534892?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534892 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06534892's enrollment target sits among peer trials
10,212 1st of 21 higher than 21 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
ACTIVE NOT RECRUITING · Phase 3
-
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
COMPLETED · Phase 3
-
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
COMPLETED · Phase 3
-
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
COMPLETED · Phase 3
-
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04332783 · 10,120 participants · NA
Isolating and Mitigating Sequentially Dependent Perceptual Errors in Clinical Visual Search
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI